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ABSTRACT
Parkinson’s disease is a debilitating movement disorder characterized by altered levels of α6β2*
nicotinic acetylcholine receptors (nAChRs) localized on presynaptic striatal catecholaminergic
neurons. α-Conotoxin MII (α-CTx MII) is a highly useful ligand to probe α6β2 nAChRs structure
and function, but it does not discriminate among closely related α6* nAChR subtypes.
Modification of the α-CTx MII primary sequence led to the identification of α-CTx MII[E11A], an
analog with 500-5300 fold discrimination between α6* subtypes found in both human and nonhuman primates. α-CTx MII[E11A] binds most strongly (femtomolar dissociation constant) to the
high affinity α6∗ nAChR, a subtype that is selectively lost in Parkinson's disease. Here we present
the three-dimensional solution structure for α-CTx MII[E11A] as determined by two-dimensional
1
H NMR spectroscopy to 0.13 +/- 0.09 Ǻ backbone and 0.45 +/- 0.08 Ǻ heavy atom root mean
square deviation from mean structure. Structural comparisons suggest that the increased
hydrophobic area of α-CTx MII[E11A] relative to other members of the α-CTx family may be
responsible for its exceptionally high affinity for α6α4β2* nAChR as well as discrimination
between α6β2 and α3β2 containing nAChRs. This finding may enable the rational design of novel
peptide analogs that demonstrate enhanced specificity for α6* nAChR subunit interfaces and
provide a means to better understand nAChR structural determinants that modulate brain
dopamine levels and the pathophysiology of Parkinson's disease.
* Indicates the possible presence of additional subunits
INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are a diverse family of ligand-gated cation channels found primarily in
neuronal and muscle cells in humans.1 Structurally, each nAChR exists as either a homopentamer of α subunits or a
heteropentamer of α and β proteins. nAChRs can be formed by any grouping of α2-α6 subunits together with β2-β4
subunits; leading to a large assortment of different receptor subtype combinations.2,3 The α6 containing nAChRs are
1
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primarily expressed at the presynaptic endings of catecholaminergic neurons in the brain, where their activity
modulates the release of dopamine (DA) and norepinephrine.4-8
α-CTx MII, isolated from the venom of Conus magus, is a potent antagonist of neuronal nAChRs.9 α-CTx MII is a
16 amino acid peptide with the sequence GCCSNPVCHLEHSNLC containing disulfide bonds connecting Cys2 to
Cys8 and Cys3 to Cys16. α-CTx MII binds to the ligand binding domain (LBD) at the interface between the α3 and β2
subunits of nAChRs and inhibits the receptor binding to acetylcholine (ACh) with an IC50 of 0.5 nM.9,10 At the time
of it’s discovery in 1997, it was thought that the α3β2 subunit combination in nAChRs of presynaptic neurons in the
brain was responsible for regulation of dopamine release into the synapse and transmission of cholinergic responses.
More recently, it has been determined that nicotinic drugs acting on the closely related α6β2* nAChRs can alter
dopamine release by DA neurons in the mid-brain and striatum.11 The reporting of α-CTx MII selectivity for α and
β subunits has led to the discovery of an additional five native α-CTxs that bind both α3β2 and α6β2 nAChRs with
variable potency and selectivity. α-CTx MII and α-CTx GIC bind to and inhibit α3β2 and α6β2 with approximately
equal preference,9,12 while α-CTx OmIA shows ~20 fold preference for α3β2 over α6β2,13 α-CTx BuIA and α-CTx
PIA show a ~20 fold and ~75 fold respective preference for α6β2 over α3β2.14,15 Each of these α-CTxs is an ACh
antagonist with an IC50 of ~0.5-1 nM (with the exception of OmIA, IC50 ~11 nM). The single-site mutant, α-CTx
MII[E11A], is a highly selective ligand for a α6α4β2* subtype of α6* nAChRs. In monkeys, α-CTx MII[E11A]
binds putative α6α4β2* nAChRs with an affinity of 9.7 fM and α6(non-α4)β2* nAChRs with an affinity of 51 pM.
Thus, α-CTx MII[E11A] discriminates between these two closely related subtypes by 5300-fold.16
Treatment with the dopaminergic neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) creates
irreversible damage that is widely used to mimic Parkinson’s disease. MPTP treatment of rodents and monkeys
leads to selective loss of the α6α4β2∗ nAChRs in the central nervous system as identified by a decrease in bound αCTx MII[E11A] in brain slice studies.16,17 Importantly, α6α4β2∗ nAChRs are also selectively lost in human
Parkinson’s disease.18 Furthermore, striatal DA-ergic fiber cells have been shown to be heterogeneous based on
nAChR subtype expression, containing two populations of DA-ergic fibers: low action potential threshold fibers
versus high action potential threshold fibers for the release of DA. α-CTx MII[E11A] binds to the low threshold
fibers whose action (DA release) is modulated by α6* nAChRs.16
Here we present the solution structure of α-CTx MII[E11A] and a structural comparison of α-CTx MII[E11A] to
other α-CTxs that bind neuronal nAChRs. A structure to activity hypothesis is proposed based on primary sequence
comparisons, mutagenesis data, and three dimensional (3D) structure features that are thought to contribute to αCTx binding potency and specificity.
MATERIALS AND METHODS
NMR Spectroscopy. An NMR sample of α-CTx MII[E11A] was initially prepared at a concentration of 4.2 mM in
90% H2O and 10% D2O (%v/v). Properly folded synthetic peptide was generously donated by the laboratory of Dr.
J. Michael McIntosh, University of Utah. High resolution 1D 1H, DQF-COSY, TOCSY and NOESY spectra were
acquired at 11.75 T on a Varian Inova spectrometer at a temperature of 15°C. Time course deuterium exchange
experiments were performed on a freeze dried sample that was re-suspended in deuterium oxide followed by data
reacquisition in 100% D2O. Subsequent high resolution 1D 1H, DQF-COSY, TOCSY, NOESY, 1H/13C HSQC, and
1
H/15N HSQC NMR spectra were performed on 0.8 mM α-CTx MII[E11A] in 95% H2O and 5% D2O at a
spectrometer field strength of 14.1 T in a Bruker Avance III spectrometer utilizing a TXI cryogenically cooled
probe. Two-dimensional 1H NMR experiments and interpretation of spectra were based on established methods.19,20
Proton DQF-COSY,21 NOESY,22 and TOCSY23 spectra were acquired with the transmitter set to 4.76 ppm and a
spectral window of 4500 Hz. Spectra in H2O were acquired with the transmitter set at 4.8 ppm and a spectral
window of 6500 Hz. Transmitter presaturation was applied at the solvent frequency to suppress the H2O resonance.
A series of NOESY spectra were acquired with mixing times of 150, 250, and 350 ms. TOCSY spectra were
acquired with mixing times of 80 ms. Slowly exchanging NH protons were detected by acquiring a series of 1D
spectra of the fully protonated peptide immediately following dissolution in 100% D2O. Spectra were processed
using Bruker TopSpin (v. 2.1), MestReC, or Varian VNMR software.
Restraint Set Generation. The 3JNH-α values for Cys2, Ser4, Leu10, Ala11, His12 and Cys16 were extracted from a high
resolution 1D 1H NMR spectrum. Backbone phi dihedral angle restraints were set to -120 +/- 40° for 3JNH-α greater
than 8.0 Hz and to -65 +/- 25° for a 3JNH-α less than 5 Hz. Inter- and intraproton distance ranges were derived from
2
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NOESY spectra recorded at 15°C. A visual analysis of peak intensity was used to assign NOE intensity as strong,
medium, or weak. As a distance reference, the intensity of the geminal protons was considered strong and the
distance constraint was set to 1.8 Å. Restraints were set to 1.8-2.7, 1.8-3.3, and 1.8-5.0 Å for strong, medium, and
weak intensity signals in the NOESY spectra. Only cross peaks that indicated reasonable correlation between the
different mixing time NOESY spectra were included as constraints for molecular dynamics calculations.24
Structure Calculations. One thousand initial structures generated from random starting conformations were input
into the CYANA (V. 2.1) software.25 The distance geometry and gradient minimization calculations were performed
to find the conformations which best modeled the 91 upper and 17 lower distance limits, 6 phi angle, 4 hydrogen
bonds, and 2 disulfide bonds consistent with the NMR data and the molecular backbone, respectively. A pseudo
atom correction of 0.5 Å was added to the upper bounds of restraints for methyl and methylene groups. The final set
of 20 structures demonstrated an overall root-mean-square deviation among backbone atoms of 0.13 +/- 0.09 Å.
RESULTS
1
Assignment of Resonances. The complete H resonance assignment for α-CTx MII[E11A] was achieved using the
method of Wüthrich.19 A combination of DQF-COSY, NOESY, and TOCSY spectra acquired at 15°C in 95% H2O
and 5% D2O were used to eliminate any ambiguities in assignment. 1H NMR spectra were observed with good
chemical shift dispersion in the amide region ranging from 9.18 to 7.45 ppm. Fourteen of the 16 amino acid spin
systems for α-CTx MII[E11A] were identified in the “fingerprint” region of a 80 ms mixing time TOCSY spectrum.
Pro6 lacks a resonance in the “fingerprint” region of the spectrum and was identified later. Gly1 was never assigned
in the TOCSY spectrum. All spin systems with the exception of Gly1 and Pro6 were confirmed in the “fingerprint”
region of a DQF-COSY spectrum and assigned to Cys2, Cys3, Ser4, Asn5, Val7, Cys8, His9, Leu10, Ala11, His12, Ser13,
Asn14, Leu15 and Cys16. Verification of α- and β-proton resonances and the location of the Pro6 spin system were
extracted from TOCSY and DQF-COSY spectra acquired in 100% D2O. A complete and thorough mapping of all
amino acid spin systems was accomplished in this manner.
The assignment of spin systems to amino acids in the primary sequence of the peptide went as follows. The methyl
region between 0.79 and 1.06 ppm in the TOCSY spectrum acquired in 95% H2O provided information needed to
identify Val7, Leu10 and Leu15. Diagnostic resonances were also seen for His9, His12 and Pro6. The imidizole ring
protons of His9 and His12 were found in the TOCSY and 1H/13C HSQC spectra between 6.99 and 8.71 ppm. The
spin system assigned to Pro6 originated at 4.26 ppm in the TOCSY spectrum. The δ-protons at 4.07 and 3.93 ppm
were helpful for assigning resonances for Pro6 because its α-proton at 4.26 ppm was within 0.01 ppm of the αprotons of His9 and Ala11. A complete trace of the Pro6 spin system was the only way to distinguish the amino acid
from those with overlapping spin systems. The remaining amino acids, Cys2, Cys3, Ser4, Asn5, Cys8, His12, Ser13,
Asn14, and Cys16 all share the same AMX pattern and were sequentially assigned from the 250 ms mixing time
NOESY spectrum by way of a “NOESY walk”.
Sequential Assignments. The NOESY data were sufficient to observe proton-proton NOE’s between the amide
proton of one residue and the α-proton of proceeding residue for Cys3, Ser4, Asn5, Cys8, His9, Leu10, Ala11, His12,
Ser13, Asn14, Leu15, and Cys16. These residues were assigned based on sequential information combined with Hβi to
HNi+1 cross peaks from the 250 ms NOESY spectrum.
Off-diagonal resonances were observed for the amide and α-protons of Cys2 at 8.89 ppm and 4.52 ppm to the βprotons of Cys3 at 3.24 and 2.84 ppm. There was a weak NOE interaction between the amide proton of Cys2 at 8.89
ppm and the β-proton of Cys8 at 3.29 ppm that helped to identify Cys8 and verify the assignment of Cys2. Likewise,
a weak NOE was observed between the amide proton of Cys3 at 8.69 and the β-protons of Cys16 at 2.63 and 2.23
ppm. A summary of restraints entered into CYANA and the results of the molecular dynamics calculations are
provided in Table 1.
-Table 1DISCUSSION
Structural description of α-CTx MII[E11A]: α-CTx MII[E11A] folds into a highly compact globular structure
consisting of a central amphipathic α-helix between residues 6-13 that is flanked by β-turns at the N- and C-termini.
Deuterium exchange studies were used to identify four hydrogen bonds that stabilize the α-helix of α-CTx
MII[E11A]. This α-helix is held in place by i to i+4 interactions between the carbonyl oxygen atoms of Pro6, Val7,
3
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Cys8, and His9, and the amide protons on Leu10, Ala11, His12, and Ser13, respectively. At the N-terminus, residues 25 are involved in a type II β-turn, stabilized by an i to i+3 hydrogen bond between the amide proton of Asn5 and the
carbonyl oxygen of Cys2. The C-terminal region exhibits a type III β-turn between Ser13 and Cys16; this turn may be
stabilized by an i to i+4 hydrogen bond between the amide proton of Cys16 and the carbonyl oxygen of Ser13,
although the amide proton of Cys16 was not observed to persist for more than 20 minutes following dissolution in
D2O. The exterior surface of the α-helix has a hydrophobic surface created by Pro6, Val7, Leu10, and Ala11 on one
side, and a hydrophilic face consisting of Cys8, His9, and Ser13 on the opposite side of the helix. Since the α-helix
has been determined to be significant for peptide activity, the potential for the cis isomer of the proline (Pro6) that
initiates the helix was explored. The presence of two strong intensity NOE cross peaks in the 350 ms mixing time
NOESY spectrum is indicative of the proximity of the Asn5 αΗ to Pro6 δH’s, and is consistent with a structure
containing the trans isomer of the Pro6 residue. 26,27 Additional inspection of the 80 ms TOCSY spectrum indicated a
single spin system for Pro6 originating at 4.26 ppm; again consistent with the trans isomer and the absence of the cis
isomer in the overall structure. Surprisingly, the hydrophobic residues of the α-helix are more exposed to the
solvent than the charged/hydrophilic residues, with the exception of His12. This residue, which has been shown to
be very significant for biological activity, is oriented toward the surface of the molecule forming its own prominent
electropositive surface feature.28
Structural Comparison between α-CTx MII[E11A] and wildtype α-CTx MII: As expected, the structure of α-CTx
MII[E11A] is very similar to that of native α-CTx MII (Figure 1). However, there are desirable differences in the
electrostatic topography of the peptide that may explain the observed enhancement in binding selectivity for the α6β2
subunit interface as compared to α3β2. As reported by both Shon et al. and Hill et al., the α-helix of α-CTx MII
originates at Pro6 and terminates at His12, while in α-CTx MII[E11A] the α-helix is observed to extend to Ser13.29,30
The increased length of the helix may be attributed to the single point mutation at Glu11. This observation is
consistent with the increase in α-helical content as measured by circular dichroism (CD) reported by Everhart et al.31
According to their analysis, α-CTx MII consists of 31.2±0.5% α-helix versus 44.9±1.3% for α-CTx MII[E11A].
The change in α-helix does not result in a dramatic change in the overall three dimensional (3D) structure, and a
change in the backbone helix itself would not be expected to be the ultimate reason for the observed changes in
specificity between α-CTx MII and the [E11A] analog.
-Figure 1There appear to be differences in the nature of the C-terminal β-loop between Ser13 and Cys16 of α-CTx MII and αCTx MII[E11A]. The C-terminal turn of α-CTx MII is described as a distorted 310-helix, whereas the C-terminal
portion of α-CTx MII[E11A] more closely resembles a type III β-turn.30 There are also differences in the orientation
of several amino acid side chains. This is probably due to the relatively few NOE constraints observed in this region
of the peptide, and does not significantly affect the results of this study. The helical portion of α4/7 conotoxins
(named according to the number of amino acids in each disulfide loop) is generally accepted to be functionally
critical in binding.12-15
In α-CTx MII there is a hydrophobic patch consisting of residues Pro6, Val7, and Leu10 on the exposed face of the αhelix. The size of this hydrophobic area is larger in α-CTx MII[E11A] with the addition of the nonpolar Ala11 side
chain. The significance of the hydrophobic regions of α-CTx MII toward binding selectivity was first demonstrated
by consecutive substitution of each peptide amino acid with alanine.28 In that study the [V7A] and [L10A]
mutations showed a relative shift in binding towards α3β2 versus α6β2 nAChRs. In α-CTx MII[V7A] and α-CTx
MII[L10A] the hydrophobicity of the amphipathic α-helix was effectively decreased by substitution of the isopropyl
or isobutyl side chains, respectively, for a methyl substituent. Conversely, alanine substitution at His9 and Asn14
increased the hydrophobic character of the α-helix, which sharpened selectivity of the peptide mutants for α6β2
versus α3β2 nAChRs. The ratios of [H9A] and [N14A] IC50 for α3β2 to α6β2 were 74.7 and 24.2, respectively,
indicating a significant enhancement of binding preference for the α6β2 subunit interface. To put this in perspective,
α-CTx MII[E11A] has an IC50 α3β2 to IC50 α6β2 ratio of 54.5, yet a 500-fold discrimination index for human and
5300-fold for monkey α6α4β2* versus α6β2* nAChRs.16
α-CTx MII [E11A] has the same secondary structure as the native peptide albeit with an extension of the α-helix,
and a distinct difference in electrostatic topography surrounding His12. In previous studies, His12 and Asn5 were
found to be important determinants of α-CTx MII potency, as was the protonation state of His12.28,31 The difference
in selectivity of α-CTx MII and α-CTx MII[E11A] may be attributed to a change in the position, orientation, or pKa
4
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of His12. The distance between the Asn5 and His12 side chains appears to be greater in α-CTx MII[E11A] than αCTx MII, but caution must be taken in structural evaluation based on side chain atom position, as the orientation of
these atoms is dynamic.
Structural Comparison between α-CTx MII[E11A] and other select α-CTxs: The NMR solution structures for αCTxs and the X-ray crystal structures that are currently available have shown that despite differences in primary
sequence there is a highly conserved secondary structural motif. It appears that α-CTx peptide binding specificity
and potency is dependent on the amino acid side chains which the backbone serves to present to the receptor on the
conserved scaffold. Table 2 shows the sequences for the α-CTxs that demonstrate binding to α3β2 and α6β2
containing nAChR. The recently reported novel α-CTx TxIA was also included due to its similarity to other α-CTxs
and because of its binding affinity to an acetylcholine binding protein from Aplysia californica (Ac-AChBP). The
Ac-AChBP serves as a model for nAChRs because it has highly conserved LBD residues, and biochemical,
pharmacological, and functional attributes consistent with indigenous nAChRs in the human body.32,33 Cocrystallization of α-CTx TxIA and Ac-AChBP demonstrate that Arg5, Asn11, and Asn12 are key side chain residues
on the peptide ligand that stabilize binding to the receptor by electrostatic and hydrogen bonding interactions.32 As
well, disulfide stacking between Cys2-Cys8 of the peptide ligand and adjacent disulfides in the receptor appear to
stabilize binding in the AChBP receptor model.32
-Table 2Previous conotoxins have been identified that bind both α6β2 and α3β2 nAChRs; these include α-CTxs MII, PIA,
GIC, BuIA and OmIA. Interestingly, α-CTxs MII[E11A], BuIA and PIA show an increased size of the hydrophobic
face of the peptide as compared to α-CTxs MII, OmIA and GIC. The size of the hydrophobic region of the
amphipathic α-helix is hypothesized to be important for selective binding of peptide to α6β2 versus α3β2 containing
nAChRs. Surface representations for these toxins and for the newly determined α-CTx MII[E11A] are shown in
Figure 2. As mentioned previously, His12 and Asn5 were found to be important determinants of α-CTx MII
potency.31 The electronic and steric character of a histidine is similar to that of an asparagine at neutral pH, and it is
worth noting that histidine and asparagine are interchangeably found in α-CTxs (Table 2, Figure 2). Either histidine
or asparagine is found in homologous locations to the His12 and Asn5 positions of α-CTx MII[E11A] in each of the
α-CTxs displayed in Figure 2, with the exception of BuIA. α-CTx BuIA has an amidated C-terminus which
occupies the same site as His12 in [E11A], which may serve as an asparagine side chain homolog for binding.
Figure 2 also shows that each of the specified α-CTxs has these residues positioned with the same orientation to
create a similar electrostatic surface for receptor interaction. The positive and negative surface charges associated
with the peptides in addition to the two disulfide bonds (shown in yellow, Figure 2) provide variation to account for
the observed binding differences from one peptide to another.
-Figure 2The crystal structures currently available to serve as binding models for the α-CTxs, contain ImI, PnIA, and Tx1A
bound in the ligand binding domain of the AChBP from Lymnea stagnalis, Botulinus subtiles, or Aplysia
californica. These X-ray crystal structures of the AChBP with bound α-CTxs ImI, PnIA, and Tx1A all indicate that
the Cys2 to Cys8 cystine bridge of the peptide is involved via disulfide bond stacking with two adjacent cysteine
residues in the receptor.33-35 Figure 2 shows that in each of these conotoxins, the Cys2 to Cys8 disulfide bridge lies
directly between either an asparagine or a histidine in the same position as Asn5 and His12 in α-CTx MII. In
addition, these toxins show a prominent and contiguous hydrophobic region of varying size on the right side of the
“front view” and the left side of the “back view” of each structure corresponding to hydrophobic residues in the αhelical portion of these peptides. This hydrophobic region is consistent with the observation that hydrophobic
interaction is a predominant factor for ligand-binding to nAChRs.36-38 It appears that the hydrophilic residues at
positions 5 and 12 (either Asn or His) in combination with the α-helix and disulfide bonds that dictate the peptide
scaffold are significant contributors to binding specificity.
Another interesting observation from this study is that the hydrophilic locus occupied by a serine following the
second cysteine in the primary sequence of each toxin is ubiquitous. α-CTxs MII, OmIA and GIC have relatively
large hydrophilic domains that are much larger than those in the other toxins, while the reduced size of this
hydrophilic domain to those found in α -CTxs PIA, BuIA and MII[E11A] may be responsible for reduced selectivity
toward binding to the α3β2 subunit interface. The back side of the toxins shows a common hydrophilic region on the
5
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left formed by three hydrophilic (polar or negatively charged) residues (Figure 2). Thus, the presence of such
common hydrophobic and hydrophilic domains, although different in their exact sizes, is likely to represent the
structural basis for binding selectivity towards α3β2 or α6β2 nAChR subtypes. These structural comparisons of αCTxs suggest that binding affinity may be caused by the hydrophobic region of the peptide while subunit binding
selectivity may be attributed to the hydrophilic patches.
ACKNOWLEDGEMENTS
This work was supported by St. Luke’s Mountain States Tumor Medical Research Institute (6PR3381000154),
Research Corporation Cottrel College Scholars Program (6PR3381000172), NIH Grant # P20 RR016454 from the
INBRE Program of the National Center for Research Resources, and the National Science Foundation CRIF-MU
program (0639251). The authors wish to thank Drs. Clemens Anklin and Donna Baldasseri at Bruker Biospin, Inc.
for helpful discussions and NMR data acquisition. In addition we would like to thank Mr. Sean Ruettgers and Mr.
Reed Jacob at Boise State University who provided technical assistance and made artistic contributions to this work.
REFERENCES
1. Lester, H. A.; Dibas, M. I.; Dahan, D. S.; Leite, J. F.; and Dougherty, D. A. Trends Neurosci. 2004, 27, 329.
2. Lindstrom, J. Ion Channels 1996, 4, 377.
3. Dani, J. A. and Bertrand, D. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 699.
4. Le Novere, N.; Zoli, M.; Changeux, J. P. Eur. J. Neurosci. 1996, 8, 2428.
5. Azam, L.; Winzer-Serhan, U. H.; Chen, Y.; Leslie, F. M. J. Comp. Neurol. 2002, 444, 260.
6. Salminen, O.; Murphy, K. L.; McIntosh, J. M.; Drago, J.; Marks, M. J.; Collins, A. C.; Grady, S. R. Mol.
Pharmacol. 2004, 65, 1526.
7. Azam, L.; McIntosh, J. M. J. Pharmacol. Exp. Ther. 2005, 312, 231.
8. Azam, L.; McIntosh, J. M. Mol. Pharmacol. 2006, 70, 967.
9. Cartier, G. E.; Yoshikami, D.; Gray, W. R.; Luo, S.; Olivera, B. M.; McIntosh, J. M. J. Biol. Chem. 1996, 271,
7522.
10. Harvey, S. C.; McIntosh, J. M.; Cartier, G. E.; Maddox, F. N.; Luetje, C. W. Mol. Pharmacol. 1997, 51, 336.
11. Drenan, R. M.; Grady, S. R.; Whiteaker, P.; McClure-Begley, T.; McKinney, S.; Miwa, J. M.; Bupp, S.; Heintz,
N.; McIntosh, J. M.; Bencherif, M.; Marks, M. J.; Lester, H. A. Neuron 2008, 60, 123.
12. McIntosh, J. M.; Dowell, C.; Watkins, M.; Garrett, J. E.; Yoshikami, D.; Olivera, B. M. J. Biol. Chem. 2002,
277, 33610.
13. Talley, T. T.; Olivera, B. M.; Han, K-H.; Christensen, S. B.; Dowell, C.; Tsigelny, I.; Ho, K-Y.; Taylor, P.;
McIntosh, J. M. J. of Biol. Chem. 2006, 281, 24678.
14. Azam, L.; Dowell, C.; Watkins, M.; Stitzel, J. A.; Olivera, B. M.; McIntosh, J. M. J. Biol. Chem. 2005, 280, 80.
15. Dowell, C.; Olivera, B. M.; Garrett, J. E.; Staheli, S. T.; Watkins, M.; Kuryatov, A.; Yoshikami, D.; Lindstrom,
J. M.; McIntosh, J. M. J. Neurosci. 2003, 23, 8445.
16. Bordia, T.; Grady, S. R.; McIntosh, J. M.; Quik, M. Mol. Pharmacol. 2007, 72, 52.
17. Meyer, E. L.; Yoshikami, D.; McIntosh, J. M. J. Neurochem. 2008, 105, 1761.
6

Turner,Eidemiller,Martin,Narver,Marshall,Zemp,Cornell, McIntosh, McDougal in Bioorganic & Medicinal Chemistry (2009)

18. Quik, M.; Bordia, T.; O’Leary, K. Biochem. Pharmacol. 2007, 74, 1224.
19. Wüthrich, K. NMR of Proteins and Nucleic Acids; Wiley: New York, 1986.
20. Bax, A. Annu. Rev. Biochem. 1989, 58, 223.
21. Rance, M.; Sørensen, O. W.; Bodenhausen, G.; Wagner, G.; Ernst, R. R.; Wüthrich, K. Biochem. Biophys. Res.
Commun. 1983, 117, 479.
22. Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. J. Chem. Phys. 1979, 71, 4546.
23. Braunschweiler, L.; Ernst, R. R. J. Magn. Reson. 1983, 53, 521.
24. Keepers, J. W.; James, T. L. J. Magn. Reson. 1984, 57, 404.
25. Güntert, P.; Mumenthaler, C.; Wüthrich, K. J. Mol. Biol. 1997, 273, 283.
26. Kaerner, A., and Rabenstein, D. L. (1999) Stability and structure-forming properties of the two disulfide bonds
of α-conotoxin GI. Biochemistry 38, 5459-5470.
27. Larive, C. K., Guerra, L., and Rabenstein, D. L. (1992) Cis/trans conformational equilibrium across cysteine6proline peptide bond of oxytocin, arginine, vasopressin, and lysine vasopressin. J. Am. Chem. Soc. 114, 73317337.
28. McIntosh, J. M.; Azam, L.; Staheli, S.; Dowell, C.; Lindstrom, J. M.; Kuryatov, A.; Garrett, J. E.; Marks, M. J.;
Whiteaker, P. Mol. Pharmacol. 2004, 65, 944.
29. Hill, J. M.; Oomen, C. J.; Miranda, L. P.; Bingham, J. -P.; Alewood, P. F.; Craik, D. J. Biochemistry 1998, 37,
15621.
30. Shon, K. -J.; Koerber, S. C.; Rivier, J. E.; Olivera, B. M.; McIntosh, J. M. Biochemistry 1997, 36, 15693.
31. Everhart, D.; Cartier, G. E.; Malhorta, A.; Gomes, A.; McIntosh J. M.; Luetje C. W. Biochemistry 2004, 43,
2732.
32. Tomizawa, M.; Maltby, D.; Medzihradszky, K. F.; Zhang, N.; Durkin, K. A.; Presley, J.; Talley, T. T.; Taylor,
P.; Burlingame, A. L.; Casida, J. E. Biochemistry 2007, 46, 8798.
33. Celie, P. H.; Kasheverov, I. E.; Mordvintsev, D. Y.; Hogg R. C.; van Nierop P.; van Elk, R.; van RossumFikkert, S. E.; Zhmak, M. N.; Bertrand, D.; Tsetlin, V.; Sixma, T. K.; Smit, A. B. Nat. Struct. Mol. Biol. 2005,
12, 582.
34. Dutertre, S.; Ulens, C.; Buttner, R.; Fish, A.; Hopping, G.; Alewood, P.; Schroeder, C.; Nicke, A.; Smit, A.;
Sixma, T.; Lewis, R. EMBO J. 2007, 26, 3858.
35. Hansen, S. B.; Talley, T. T.; Radic, Z.; Taylor, P. J Biol. Chem. 2004, 279, 24197.
36. Bren, N.; Sine, S. M. J. Biol. Chem. 2000, 275, 12692.
37. Quiram, P. A.; McIntosh, J. M.; Sine, S. M. J. Biol. Chem. 2000, 275, 4889.
38. Bourne, Y.; Talley, T. T.; Hansen, S. B.; Taylor, P.; Marchot, P. EMBO J. 2005, 24, 1512.

7

Turner,Eidemiller,Martin,Narver,Marshall,Zemp,Cornell, McIntosh, McDougal in Bioorganic & Medicinal Chemistry (2009)

LEGENDS
Figure Captions
1. A structure comparison of α-CTxs MII (top row) and E11A (bottom row). From left to right, an overlay of the 20
backbone atoms for the final 20 structures (for MII, Shon et al. structure) with the N- and C-termini labeled, a tube
structure with Pro6 labeled as the point of initiation of the α-helix and residues in positions 11 and 12 labeled, and
lastly, the surface of each peptide colored by atom charge where red is negative, blue is positive, and white is neutral
for the peptides at a pH of 3.
2. Surface comparison of α-CTxs PIA, MII[E11A], BuIA, MII, GIC, OmIA from top to bottom, respectively. Blue
regions represent electropositive surfaces, red regions are electronegative surfaces, and white/faintly colored regions
are hydrophobic/nonpolar surfaces. Sulfur atoms of cystine residues are yellow. Left panel: front view of peptide
surface. Right panel: backside view of peptide surface.
Table Captions
1. Restraints and structural statistics for the final 20 structures generated by the CYANA software based on NMR
derived constraints for α-CTx MII[E11A].
2. Primary sequence comparison of α-CTxs that bind to both α3β2 and α6β2 subtype nAChRs. The scaffold disulfide
bond motif common to these conotoxins is shown for PIA. Included are the IC50 values for α3β2 and α6β2 subtype
nAChR and the PDB code for each conotoxin.
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Figure 1
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Figure 2
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Table 1
Parameter
Number of NOE distance constraints
Intra-residue
Sequential
Medium range
Long range
Dihedral angle restraints
Hydrogen bond constraints
Ramachandran plot regions (%)
Most favored region
Additionally allowed region
Generously allowed region
Disallowed region
RMSDs from the average structure (Å)
Backbone atoms
Heavy atoms

Value
92
16
27
32
17
6
4
51.9
40.4
7.7
0.0
0.13 ± 0.09
0.42 ± 0.08

Table 2
α-CTx
PIA
MII[E11A]
BuIA
MII
GIC
OmIA
TxIA

11

Primary Sequence
RDPCCSNPVCTVHNPQIC
GCCSNPVCHLAHSNLC
GCCSTPPC---AVLYC
GCCSNPVCHLEHSNLC
GCCSHPACAGNNQHIC
GCCSHPACNVNNPHICG
GCCSRPPCIANNPDLC

IC50 α3β2
nM
74.20
8.72
5.72
2.20
1.10
11.00
3.50

IC50 α6β2
nM
0.95
0.16
0.26
0.39
~3
201
N/A

Ratio IC50
α3β2 to α6β2
78.1
54.5
22.0
5.6
0.4
0.0547
N/A

Reference

PDB

[15]
[26]
[14]
[9]
[12]
[13]
[32]

1ZLC
-2I28
1M2C
1UL2
2GCZ
U2Z6
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